iCAD (NASDAQ:ICAD) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of iCAD (NASDAQ:ICAD) from a sell rating to a hold rating in a research note released on Thursday.

iCAD Stock Performance

Shares of iCAD stock opened at $1.54 on Thursday. iCAD has a 1-year low of $1.18 and a 1-year high of $2.65. The firm’s 50-day moving average price is $1.72 and its two-hundred day moving average price is $1.54. The stock has a market capitalization of $40.87 million, a price-to-earnings ratio of -11.85 and a beta of 1.47.

Institutional Trading of iCAD

Several large investors have recently made changes to their positions in the business. Virtu Financial LLC boosted its position in iCAD by 55.6% in the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after buying an additional 7,604 shares during the last quarter. Perritt Capital Management Inc raised its stake in shares of iCAD by 14.2% during the second quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock worth $208,000 after buying an additional 19,917 shares during the last quarter. Essex LLC bought a new position in iCAD in the third quarter valued at approximately $216,000. Finally, Perritt Capital Management Inc. grew its holdings in iCAD by 7.5% during the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock worth $225,000 after acquiring an additional 9,717 shares during the period. Institutional investors own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.